Ampio Pharmaceuticals (NY: AMPE )

0.8332 USD +0.0102 (+1.24%)

Official Closing Price Updated: 8:00 PM EDT, Oct 21, 2020 Add to My Watchlist

Price and Volume

Volume	619,100
Open	0.8090
Bid (Size)	0.8200 (12)
Ask (Size)	0.8364 (1)
Prev. Close	0.8230
Today's Range	0.8000 - 0.8494
52wk Range	0.2600 - 1.390
Shares Outstanding	86,320,968
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

October 08, 2020

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the...

Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer

September 29, 2020

Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today...

Performance

YTD	+41.89%	+41.89%
1 Month	-22.85%	-22.85%
3 Month	+5.47%	+5.47%
6 Month	+67.21%	+67.21%
1 Year	+84.25%	+84.25%

More News

FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress

September 21, 2020

Ampion Phase I COVID-19 Patient Trial Results Featured on FOX News (Video)

September 14, 2020

Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients

September 09, 2020

Ampio Announces Enrollment Completion for Intravenous ("IV") COVID-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee ("OAK") Clinical Trial

September 04, 2020

Ampio Provides Update on COVID-19 Clinical Trial Activities

August 19, 2020

Researchers Identify Potent Infection-Blocking Antibodies In Race For COVID-19 Vaccine

July 28, 2020

Researchers Identify Potent Infection-Blocking Antibodies In Race For COVID-19 Vaccine

July 28, 2020

Ampio Starts Patient Enrollment in its Ampion COVID-19 Program

July 23, 2020

Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 related Syndrome

July 20, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.